Nothing Special   »   [go: up one dir, main page]

ES2180417A1 - Novel overexpressed protein in prostate cancer - Google Patents

Novel overexpressed protein in prostate cancer

Info

Publication number
ES2180417A1
ES2180417A1 ES200100592A ES200100592A ES2180417A1 ES 2180417 A1 ES2180417 A1 ES 2180417A1 ES 200100592 A ES200100592 A ES 200100592A ES 200100592 A ES200100592 A ES 200100592A ES 2180417 A1 ES2180417 A1 ES 2180417A1
Authority
ES
Spain
Prior art keywords
protein
novel
overexpressed
prostate cancer
prostate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES200100592A
Other languages
Spanish (es)
Other versions
ES2180417B1 (en
Inventor
Okatsu Timothy Thomson
Hernandez Patricia Benedir
Barzanti Kosanna Pacciucci
Robles Joan Morote
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
INSTO CATALAN de la SALUD HOSP
Consejo Superior de Investigaciones Cientificas CSIC
Fundacio Hospital Universitari Vall dHebron Institut de Recerca FIR VHIR
Original Assignee
INSTO CATALAN de la SALUD HOSP
Consejo Superior de Investigaciones Cientificas CSIC
Fundacio Hospital Universitari Vall dHebron Institut de Recerca FIR VHIR
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by INSTO CATALAN de la SALUD HOSP, Consejo Superior de Investigaciones Cientificas CSIC, Fundacio Hospital Universitari Vall dHebron Institut de Recerca FIR VHIR filed Critical INSTO CATALAN de la SALUD HOSP
Priority to ES200100592A priority Critical patent/ES2180417B1/en
Priority to PCT/ES2002/000122 priority patent/WO2002072633A1/en
Publication of ES2180417A1 publication Critical patent/ES2180417A1/en
Application granted granted Critical
Publication of ES2180417B1 publication Critical patent/ES2180417B1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention relates to a novel overexpressed gene and protein in prostate cancer that has been identified and sequenced and the invention demonstrates that said protein is overexpressed in prostate adenocarcinoma using the western-blot and RT-PCR technique. The expression of said protein is correlated with the proliferation of tumours. Specific antibodies have been generated that specifically detect the protein both in cell lines and in human normal and tumour tissue using immunological methods. Using said antibodies, the invention demonstrates that the protein is overexpressed in the majority of human prostate adenocarcinomas and, therefore, the detection of said transcript and protein constitutes a novel marker for this type of tumour, with potential use in the diagnosis thereof. Furthermore, said protein is a target protein. The invention also relates to the identification of compounds for antitumour therapies.
ES200100592A 2001-03-14 2001-03-14 NEW OVEREXPRESSED PROTEIN IN CANCER DE PROSTATA. Expired - Fee Related ES2180417B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
ES200100592A ES2180417B1 (en) 2001-03-14 2001-03-14 NEW OVEREXPRESSED PROTEIN IN CANCER DE PROSTATA.
PCT/ES2002/000122 WO2002072633A1 (en) 2001-03-14 2002-03-14 Novel overexpressed protein in prostate cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200100592A ES2180417B1 (en) 2001-03-14 2001-03-14 NEW OVEREXPRESSED PROTEIN IN CANCER DE PROSTATA.

Publications (2)

Publication Number Publication Date
ES2180417A1 true ES2180417A1 (en) 2003-02-01
ES2180417B1 ES2180417B1 (en) 2004-05-16

Family

ID=8497077

Family Applications (1)

Application Number Title Priority Date Filing Date
ES200100592A Expired - Fee Related ES2180417B1 (en) 2001-03-14 2001-03-14 NEW OVEREXPRESSED PROTEIN IN CANCER DE PROSTATA.

Country Status (2)

Country Link
ES (1) ES2180417B1 (en)
WO (1) WO2002072633A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004067560A2 (en) * 2003-01-27 2004-08-12 Gsf - Forschungszentrum Für Umwelt Und Gesundheit, Gmbh Herpes simplex vp16 protein binding polypeptides

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001007474A1 (en) * 1999-07-28 2001-02-01 Kelvin Stott Peptides containing n-substituted d-amino acids for preventing beta-strand association

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6111800A (en) * 1999-07-21 2001-02-13 Human Genome Sciences, Inc. 26 human prostate and prostate cancer associated proteins

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001007474A1 (en) * 1999-07-28 2001-02-01 Kelvin Stott Peptides containing n-substituted d-amino acids for preventing beta-strand association

Also Published As

Publication number Publication date
WO2002072633A1 (en) 2002-09-19
ES2180417B1 (en) 2004-05-16

Similar Documents

Publication Publication Date Title
Grigoriu et al. Endocan expression and relationship with survival in human non–small cell lung cancer
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
AU1726199A (en) Metastatic cancer regulated gene
WO2005100998A3 (en) Membrane markers for use in cancer diagnosis and therapy
WO2003083096A3 (en) Cancer associated protein kinases and their uses
EP2261369A3 (en) Gene expression profiling in biopsied tumor tissues
MY183404A (en) Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
AU2002246668A1 (en) Monoclonal antibodies and cell surface antigens for the detection and treatment of small cell lung cancer (sclc)
Takahashi et al. RCAS1 antigen is highly expressed in extramammary Paget's disease and in advanced stage squamous cell carcinoma of the skin
AU2015343425A1 (en) Anti-galectin antibody biomarkers predictive of anti-immune checkpoint and anti-angiogenesis responses
WO2003069307A3 (en) Claudins, markers for diagnosis, prognosis and therapy of breast, bone, brain cancer
WO2002024947A3 (en) Cancer associated protein kinases and their uses
Lavens et al. EGFR overexpression in squamous cell carcinoma of the penis
EP1887082A3 (en) TADG-15: An extracellular serine protease overexpressed in carcinomas
WO2003070889A3 (en) Prostate specific genes and the use thereof in design or therapeutics
ES2180417A1 (en) Novel overexpressed protein in prostate cancer
AU3556901A (en) Use of anti-ferritin monoclonal antibodies in the treatment of some cancers
Bochis et al. The prognostic role of Skp2 and the tumor suppressor protein p27 in colorectal cancer
Salama et al. Clinical significance of the transcription factor sox11, cell-cell adhesion protein e-cadherin and zinc finger protein bcl11a in the diagnosis of breast cancer
WO2023214358A3 (en) Foxc1 expression as a complementary diagnostic assay for predicting efficacy of oncology drugs and drug combination regimens and methods for use
WO2004013631A3 (en) Compositions and methods for diagnosis and therapy of cancer
WO2003024302A3 (en) Detection and treatment of cancers of breast
MX2023010825A (en) Methods for treating cancer with anti-ilt3 antibodies.
WO2001055391A3 (en) 84p2a9: a prostate and testis specific protein highly expressed in prostate cancer
Richter et al. Primary cervical carcinoma cell lines overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20030201

Kind code of ref document: A1

FG2A Definitive protection

Ref document number: 2180417B1

Country of ref document: ES

FD2A Announcement of lapse in spain

Effective date: 20180807